GuidelineBlood2020
ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic.
Guideline in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 6 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Digital transfer in radiation oncology education for medical students-single-center data and systemic review of the literature.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Pooled it
- Radiotherapy based management during Covid-19 pandemic - A systematic review of presented consensus and guidelines.Critical reviews in oncology/hematology · 2021Pooled it
- Pooled it
- Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic : Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Guideline
- Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group.Journal of geriatric oncology · 2020Guideline
- [Practical guidelines for the radiotherapy for patients presented with haematological malignancies in the epidemic COVID-19 situation: International Lymphoma Radiation Oncology Group recommendations].Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2020Guideline
- Acute and sub-acute toxicity profile of ultra-hypofractionated low-dose total skin electron beam with two 4 Gy fractions for cutaneous T cell lymphoma.Journal of cancer research and clinical oncology · 2021Trial
- Dose-de-escalated focal radiotherapy for primary cutaneous T-cell lymphoma: a lesion-based retrospective cohort study.Acta oncologica (Stockholm, Sweden) · 2026Article
- Role of Radiotherapy in the Era of Novel Immune-Based Treatment Strategies for Multiple Myeloma.Hematological oncology · 2026Review
- Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025Article
- Article
- Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience.Current oncology (Toronto, Ont.) · 2025Article
- Total skin electron beam therapy.Frontiers in oncology · 2025Article
- Knowledge and competences in hematological malignancies amongst radiation oncology residents in Germany-results from a national survey.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Personalised therapy in follicular lymphoma - is the dial turning?Hematological oncology · 2024Review
- Impact of the COVID-19 Pandemic on Hypofractionated Radiation Therapy Use for Breast Cancer in Japan: A Nationwide Study.Advances in radiation oncology · 2024Article
- Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era.BMC cancer · 2024Article
- Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond.Current oncology (Toronto, Ont.) · 2024Article
- Cancer management during the COVID-19 world pandemic.Cancer immunology, immunotherapy : CII · 2023Review
- Impact of the COVID-19 pandemic on training conditions and education in oncologic disciplines: a survey-based analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.